Liver fibrosis has evolved in the past 20 years from a pure laboratory discipline to an area of
great bedside relevance to practicing hepatologists. This evolution reflects growing awarenessnotonlyofthemolecularunderpinn …

Worldwide, chronic hepatitis B virus (HBV) infection is the primary cause of cirrhosis and
hepatocellular carcinoma and is one of the ten leading causes of death. Traditionally …

Chronic infection with the hepatitis B virus (HBV) is estimated to affect 400 million persons
and to be the single most common cause of cirrhosis and hepatocellular carcinoma (HCC) …

Thirty years ago, the diagnosis of chronic hepatitis B (CHB) was thought to require the
presence of hepatitis B e antigen (HBeAg), as a reliable and sensitive marker of hepatitis B …

As novel therapies for liver fibrosis evolve, non‐invasive measurement of liver fibrosis will be
required to help manage patients with chronic liver disease. Although liver biopsy is the …

The goals of this retrospective study were to determine whether there is a threshold hepatitis
B virus (HBV) DNA value associated with spontaneous or antiviral therapy–related hepatitis …

Currently, compounds under evaluation for treatment of chronic hepatitis B virus (HBV)
infection are evaluated with liver histology as the primary end point for efficacy. However …

BACKGROUND & AIMS:: Hepatitis B virus (HBV) genotype may influence disease
progression and antiviral response. We therefore analyzed the frequency and distribution of …

Phylogenetic analysis has led to the classification of hepatitis B virus into eight genotypes,
designated A to H. The genotypes have differences in biological properties and show …

The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen
(HBeAg)‐negative chronic hepatitis is unclear. In a retrospective multicenter study, we have …